Kedalion Therapeutics

Kedalion Therapeutics Overview

  • Founded
  • 2015
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Latest Deal Amount
  • $5M
Latest Deal Amount
  • Investors
  • 1

Kedalion Therapeutics General Information


Developer of an ophthalmic therapy technology designed to bring to market transformative topical ophthalmic drugs for new and existing indications. The company's technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable efficacy with an 80% reduction in dose compared to standard drops, and a significantly improved side effect profile along with patient comfort and convenience following self-administration, enabling healthcare professionals and physicians to impart more comfort and convenience to the patients that are associated with fewer side effects, while reducing the burden on healthcare system.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Primary Office
  • 1490 O'Brien Drive
  • Suite C
  • Menlo Park, CA 94025
  • United States
+1 (650) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Kedalion Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 06-Aug-2018 $5M 00.00 0000 Completed Product Development
1. Seed Round 04-Dec-2015 00000 00000 00.00 Completed Startup

Kedalion Therapeutics Cap Table

To view Kedalion Therapeutics‘s complete cap table, request access »
Stock # of Shares
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00.00 00.00 00.00 00 00.00 00.000
Seed 0,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000

Kedalion Therapeutics Executive Team (5)

Name Title Board Seat Contact Info
Mark Murray Chief Financial Officer
Ehud Ivri Chief Technology Officer & Co-Founder
Casey Dougan Chief Commercial Officer & Vice President, Operations
Mark Blumenkranz MD Co-Founder, Chief Executive Officer & Chairman

1 Former Executive

Kedalion Therapeutics Board Members (5)

To view Kedalion Therapeutics‘s full board member team, request access »
Name Representing Role Since
Dana Mead Jr. Self Board Member 000 0000
Darius Kharabi JD Lagunita BioSciences Board Member 000 0000
John Power Self Board Member 000 0000
Marc Gleeson Self Board Member 000 0000

1 Former Board Member

Kedalion Therapeutics Investors (1)

To view Kedalion Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Lagunita BioSciences Venture Capital Minority 000 0000 000000 0

Ready to get started?

Request a free trial